Appetite suppressants and valvular heart disease - a systematic review. - Wikidata - awgldk - TriplyDB

Appetite suppressants and valvular heart disease - a systematic review.

Appetite suppressants and valvular heart disease - a systematic review.

http://www.wikidata.org/entity/Q24802870

about

Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals Risk of valvular heart disease associated with use of fenfluramine Pharmacotherapies for obesity: past, current, and future therapies Serotonergic drugs and valvular heart disease Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended event Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial.Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review.Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity.Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population.Cardiac effects of MDMA on the metabolic profile determined with 1H-magnetic resonance spectroscopy in the rat.

P2860

Q21245270-4782C115-44AD-407C-BFFB-AA1687C1F20F Q21261946-C9B92D0F-F54F-4ABA-82E4-4E0D60C6CA49 Q21296814-3C2F8D2D-A854-42EE-83FD-CA727A358EAC Q24646869-82226C2B-71CA-41CB-8423-87379AF1E6EA Q33692818-49F7E784-BA9D-4803-B7DD-B767FAF76B62 Q34254787-C5BEA12F-FBD8-4AC6-87AA-04F8E5CA7B24 Q34533195-B0949A6B-A3B2-4FD3-9CD2-93219A482A85 Q34962263-6BAEAA9A-92A7-49CE-A48F-591A26E7561E Q36784255-FA4075BE-41FE-4384-9793-42741F812AD8 Q37310802-59EE4AA2-E8A9-491A-BA22-80B5B441A7FC Q38031743-8F876005-39DE-409E-B16E-81F0F83E0573 Q38681023-529CCC30-7727-4975-ACA2-C8BE5BF35701 Q40950605-9B7F3D40-D824-4119-957F-2BD527FAD337

P2860

Appetite suppressants and valvular heart disease - a systematic review.

http://www.wikidata.org/entity/Q24802870

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Appetite suppressants and valvular heart disease - a systematic review

@nl

Appetite suppressants and valvular heart disease - a systematic review.

@ast

Appetite suppressants and valvular heart disease - a systematic review.

@en

type

label

Appetite suppressants and valvular heart disease - a systematic review

@nl

Appetite suppressants and valvular heart disease - a systematic review.

@ast

Appetite suppressants and valvular heart disease - a systematic review.

@en

prefLabel

Appetite suppressants and valvular heart disease - a systematic review

@nl

Appetite suppressants and valvular heart disease - a systematic review.

@ast

Appetite suppressants and valvular heart disease - a systematic review.

@en

P1433

Q24802870-0AF452F2-4DCC-49EA-B78E-3552E3CF8E10

P1476

Q24802870-07A0C6D2-11C6-4911-81C1-B827C5D5F7CD

P2093

Q24802870-A1377EF0-A162-4F3A-A1BF-65A66C854D70

Q24802870-BAA7604B-9491-40A2-B59F-57BC248AF2F5

P2860

Q24802870-0F250551-AEF1-4544-B02C-13909B4026FE

Q24802870-12B3D3CE-21B1-442D-8AD7-E36C803B4A0D

Q24802870-14E8047B-27F1-4B93-95C5-040453EFBBAD

Q24802870-20D7BE25-738F-4BAD-8A62-BEFD2AABC372

Q24802870-263AFA54-FD46-475B-8414-22E319BA863E

Q24802870-32850E3A-E26A-49C2-849C-172C64973788

Q24802870-3739F4A4-7B2A-4F10-940C-04C714C3441E

Q24802870-3DB95313-7270-43D4-BEA0-883D9B97BD42

Q24802870-4218718B-D094-469C-B734-CE6935622884

Q24802870-51A8E7E2-3FAE-4AF2-9DB0-6490316150B8

P2888

Q24802870-F7AB3902-D768-460A-88DE-66E2D189C3A3

P304

Q24802870-EC488C83-DAA3-4129-A5FF-36863F9F48AA

P31

Q24802870-57D5DBC6-D9A2-4702-A0F7-82ECFDCFCDCA

Q24802870-76A53EBB-141A-4909-B62D-393ED995B2C0

Q24802870-AF3268F8-E436-4A92-A1C0-04FB11212733

P356

Q24802870-132E50B2-FB1A-4760-91DC-E0D07C4F3E9E

P407

Q24802870-F4917CF7-A4E6-4E79-91B2-A669AC091DD1

P433

Q24802870-15AA1E29-5088-4808-8369-3FCA29832792

P478

Q24802870-7D42D5FD-9D91-49ED-84EA-86AF7415A9B8

P50

Q24802870-C7F12F89-9B33-4542-8690-71240C0E2A10

P577

Q24802870-F1F09ADD-D9E3-433D-BBE9-2D325CEE5D57

P5875

Q24802870-B1F51B06-A791-4B90-9C59-E1EA42A2B173

P6179

Q24802870-B8685B94-A97D-4CBD-99EA-B619455BE1B2

P698

Q24802870-D3A675FC-A99B-4E91-9F1B-59F8BE6102D2

P921

Q24802870-629D06C8-0BA0-4CDC-816D-76CC5AE24D22

Q24802870-B23473D9-A8C7-40A9-822D-A10E2A030910

P932

Q24802870-3A0A9AA3-6223-4AD7-844F-E5B98BA85ABF

P356

P1433

BMC Clinical Pharmacology

P1476

Appetite suppressants and valvular heart disease - a systematic review.

@en

P2093

Angharad Pritchard-Copley

http://www.w3.org/2001/XMLSchema#string

Yoon K Loke

http://www.w3.org/2001/XMLSchema#string

P2860

Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine

Valvular heart disease associated with fenfluramine-phentermine

Aminorex to fen/phen: an epidemic foretold

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities

Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.

P2888

P304

6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P356

10.1186/1472-6904-2-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11192977

http://www.w3.org/2001/XMLSchema#string

P6179

1002212633

http://www.w3.org/2001/XMLSchema#string

P698

12194699

http://www.w3.org/2001/XMLSchema#string

P921

heart valve disease

P932

126245

http://www.w3.org/2001/XMLSchema#string